Eli Lilly and Company entered into a definitive agreement to acquire AtaiBeckley, a clinical-stage biopharmaceutical company developing neuroplastogen-based treatments for mental health conditions.

Per the terms of the agreement, Lilly is set to pay $6.75 per share in cash at closing, representing an aggregate equity value of approximately $2.8 billion, plus contingent value rights of up to $2.50 per share tied to development and regulatory milestones, bringing total potential consideration to approximately $3.8 billion.¹

The deal carries a premium of approximately 40% to AtaiBeckley's 30-day volume-weighted average trading price end on July 15, 2026.¹ The transaction is expected to close in the third quarter of 2026, subject to AtaiBeckley shareholder approval and customary regulatory clearances.

Christian Angermayer, founder, largest shareholder and chairman of the board of AtaiBeckley, framed the sale as the fastest path to patients. "From Atai's founding, our mission has been to bring transformative mental health treatments to the patients who need them most. Joining Lilly gives this pipeline, and the patients waiting for it, the benefit of the resources and scale Lilly has to potentially advance therapies faster than we could alone," Angermayer said.

What is AtaiBeckley developing?

AtaiBeckley is advancing a pipeline of rapid-acting neuroplastogens, compounds designed to restore synaptic plasticity rather than simply modulate neurotransmitter levels. The lead asset, Bpl-003 (mebufotenin benzoate), is a synthetic, intranasally administered form of 5-MeO-DMT being developed for treatment-resistant depression, a condition that affects millions of Americans and persists even after multiple prior treatment failures.²

In a Phase II study, Bpl-003 demonstrated rapid and durable reductions in depressive symptoms following an in-clinic visit lasting approximately two hours on average, with effects persisting for months.² FDA has already granted Bpl-003 Breakthrough Therapy Designation and the program has begun initiating Phase III activities.

AtaiBeckley’s second most advanced asset, Vls-01, is a buccal film formulation of DMT currently being evaluated in an ongoing Phase IIb study.³ Under the CVR terms, Lilly is set to pay $1.00 per share upon initiation of a Phase III trial for Vls-01 before the fourth anniversary of closing; $0.50 per share upon U.S. regulatory approval and DEA rescheduling of Bpl-003 before the fifth anniversary; and $1.00 per share upon U.S. regulatory approval and DEA rescheduling of Vls-01 before the seventh anniversary.¹

What is the scientific rationale?

AtaiBeckley's therapies aim to promote the growth of new neural connections, representing a mechanistically distinct approach from conventional antidepressants that primarily target neurotransmitter reuptake or receptor binding.

"Across our portfolio, we're seeking to demonstrate that psychiatric illness is treatable at its biological root, not just its symptoms," said Srinivas Rao, co-founder and chief executive officer of AtaiBeckley. "Lilly's expertise and reach are expected to accelerate that work for people whose conditions have not responded to existing treatments."

What does Lilly say?

Carole Ho, executive vice president and president of Lilly Neuroscience, pointed to the unmet need in treatment-resistant depression as the driving rationale, saying: "Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works. Advancing AtaiBeckley's investigational therapies gives us a real chance to change that."

Apeiron Investment Group and all directors and officers of AtaiBeckley have signed voting and support agreements covering approximately 15% of AtaiBeckley's outstanding common stock.

Sources

1. Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions Eli Lilly and Company July 16, 2026 https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-ataibeckley-advance-therapies-treatment-resistant
2. AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs AtaiBeckley April 8, 2026 https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckleys-bpl-003-shows-rapid-durable-antidepressant-response/
3. AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder AtaiBeckley July 6, 2026 https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-doses-last-patient-vls-01-phase-2b-trd-study-plans